Last reviewed · How we verify
opioid-sparing group
opioid-sparing group is a Small molecule drug developed by University Hospital, Basel, Switzerland. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | opioid-sparing group |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache/Migraine
- Inadequate Regional Anesthesia
Key clinical trials
- Virtual Reality for Postoperative Recovery After Major Abdominal Surgery (NA)
- Analgesic Techniques for Robotic Prostatectomy Procedures (NA)
- Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery (PHASE2, PHASE3)
- Preop US-Guided Nerve Blocks for Pain & Recovery After Ankle Arthroscopy (NA)
- NeuroCuple to Mitigate Post-Wisdom Teeth Extraction Opioid Risks (NA)
- Preoperative Deep Parasternal Intercostal Plane Block and Intraoperative Opioid Use in Cardiac Surgery (NA)
- Prediction and Prevention of Postoperative Mortality and Morbidity (NA)
- Ketamine Administration for Postoperative Pain Management in Patients Undergoing Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- opioid-sparing group CI brief — competitive landscape report
- opioid-sparing group updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI
Frequently asked questions about opioid-sparing group
What is opioid-sparing group?
Who makes opioid-sparing group?
What development phase is opioid-sparing group in?
What are the side effects of opioid-sparing group?
Related
- Manufacturer: University Hospital, Basel, Switzerland — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing